OLFM1 Antibody

What is OLFM1 and why is it important in research?

OLFM1 (also known as noelin and pancortin) is a secreted glycoprotein belonging to the olfactomedin domain-containing protein family. It is highly conserved across species, with 98% amino acid sequence identity between mouse and human, and 84% between mouse and zebrafish . OLFM1 is notably expressed in the developing nervous system, specifically in neural crest derivatives and their tissue derivatives . The protein plays crucial roles in:

• Neural progenitor maintenance

• Neuronal differentiation

• Regulation of axonal growth

• Cell death processes in the brain

• Optic nerve arborization

OLFM1 forms disulfide-linked tetramers with a distinctive V-shaped architecture, suggesting a role in receptor clustering and signaling regulation . This structural arrangement consists of:

• A base formed by two disulfide-linked dimeric N-terminal domains

• Two V-legs each composed of parallel dimeric disulfide-linked coiled coils

• C-terminal β-propeller dimers at the tips

What antibody types are available for OLFM1 research?

Two main types of antibodies against OLFM1 have been documented in the research literature:

• Monoclonal antibodies: Generated against specific peptide sequences such as SRDARTKQLRQLLEKVQN. These antibodies typically detect denatured protein on Western blots and antigen-retrieved proteins on histological sections .

• Polyclonal antibodies: Generated against purified Olfm1 protein. These antibodies can detect intact OLFM1 and are suitable for immunoprecipitation and immunofluorescence applications .

How should OLFM1 antibodies be handled and stored for optimal results?

For optimal performance of OLFM1 antibodies, follow these methodological guidelines:

• Storage conditions: Store at -20°C. Most preparations are stable for one year after shipment .

• Buffer composition: Typically stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Aliquoting: For most commercial preparations, aliquoting is unnecessary for -20°C storage .

• Dilution optimization: Antibodies should be titrated in each testing system to obtain optimal results, as optimal dilutions are sample-dependent .

• Antigen retrieval: For IHC applications, suggested antigen retrieval with TE buffer pH 9.0; alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 .

How can I validate the specificity of OLFM1 antibodies for particular isoforms?

Validating OLFM1 antibody specificity is challenging due to the existence of multiple splice variants. Four variant transcripts (AMY, BMY, AMZ, and BMZ) are produced by alternative splicing . To validate specificity:

• Expression system testing: Test antibodies against COS7 or HEK293 cells transiently transfected with constructs encoding different OLFM1 isoforms .

• Cross-reactivity assessment: Verify the antibody does not recognize closely related family members like Olfactomedin 2 (Olfm2) or Olfactomedin 3 (Olfm3) .

• Isoform-specific detection: Some antibodies are specific for particular isoforms. For example, certain commercially available antibodies are specific for isoform 3 and isoform 4 (AMY) of OLFM1 with native molecular weights of 54 kDa and 16 kDa respectively .

• Genetic models: Use transgenic models such as TG(Olfm1:EGFP) mice that contain bacterial artificial chromosomes with EGFP sequences inserted downstream of OLFM1 for antibody validation .

What are the optimal conditions for using OLFM1 antibodies in different experimental applications?

Different experimental applications require specific optimization strategies:

For Western Blotting:

• Use reducing or non-reducing conditions based on research objectives

• For reducing conditions: Add 6% (v/v) β-mercaptoethanol to SDS loading dye

• For non-reducing SDS-PAGE: Omit reducing agents to preserve disulfide bonds

• Run samples on standard Laemmli 12.5% (w/v) polyacrylamide Tris-glycine gels

For Immunohistochemistry:

• Antigen retrieval protocol significantly impacts results

• For optimal staining, use TE buffer pH 9.0 or alternative citrate buffer pH 6.0

• Antibody dilution range should be tested (typically 1:20-1:200 for polyclonal antibodies)

For Coimmunoprecipitation:

• Consider using polyclonal antibodies that can recognize native protein conformations

• Be aware that glycosylation status affects interaction detection (extracellular vs. intracellular interactions)

How does OLFM1 influence axonal growth and how can antibodies target this process?

OLFM1 regulates axonal growth through its interaction with the Nogo A receptor (NgR1) complex:

• Mechanism of action: OLFM1 binds specifically to NgR1 with a calculated Kd of 9.5 ± 0.7, and this binding reduces the association of NgR1 with its coreceptors p75NTR and LINGO-1 .

• Functional consequences: OLFM1 inhibits growth cone collapse of dorsal root ganglia neurons induced by myelin-associated inhibitors, including MAG-Fc and Nogo A-Fc .

• Antibody applications: Function-blocking OLFM1 antibodies can be used at concentrations of approximately 10 μg/ml to study these interactions in experimental settings. These antibodies inhibit mesenchymal cell formation in the presence of exogenous OLFM1, demonstrating specific blockade of OLFM1 function .

• Signaling pathway analysis: Antibodies can be used to investigate how OLFM1 affects RhoA activity. Research shows that OLFM1 pretreatment reduces MAG-Fc-induced RhoA-GTP activation to control levels in both COS7 cells and at the tips of dorsal root ganglia growth cones .

What role does OLFM1 play in cancer metastasis and how can antibodies be used to study this process?

OLFM1 has been implicated in promoting metastatic processes, particularly in neuroblastoma (NB):

• Metastatic mechanism: Signals released by embryonic sympathetic ganglia, including OLFM1, induce NB cells to shift from a noradrenergic to mesenchymal identity, activating gene programs that promote metastatic onset and dissemination .

• Experimental approaches:

  • Exposure of NB aggregates to increasing doses of recombinant OLFM1 (rOLFM1) triggers significant and dose-dependent loss of cell-cell cohesion .

  • In transwell migration and invasion assays, increasing doses of rOLFM1 promote NB cell motility .

• Antibody blocking studies: Anti-OLFM1 antibodies with function-blocking activity can almost completely abolish the effects of embryonic sympathetic ganglia conditioned media on NB cell-cell cohesion and motility/invasion properties .

• In vivo models: Intravenous injection of OLFM1 antibodies in avian embryo models of NB significantly reduces:

  • NB cell escape from primary tumors

  • Number of metastatic foci

  • Distance of metastatic spread from primary tumors

Importantly, OLFM1 antibody treatment does not affect normal sympathetic neuron aggregation, making it a potentially selective therapeutic target for neuroblastoma metastasis .

What considerations should be made when selecting antibody epitopes for OLFM1 research?

When selecting or designing antibodies against OLFM1, consider:

• Domain-specific targeting:

  • N-terminal domain antibodies: Target the region involved in dimerization and oligomerization

  • M domain antibodies: Focus on the central region containing cysteine residues critical for dimerization and oligomerization

  • Olfactomedin domain antibodies: Target the β-propeller domain involved in protein-protein interactions

• Structural accessibility:

  • The V-shaped tetrameric structure of OLFM1 affects epitope accessibility

  • The β-propeller top faces have outward exposed orientation, making them more accessible targets

• Specificity considerations:

  • The cysteine residues in the central M part are critical for dimerization and oligomerization

  • The N-terminal domain (residues 17-478 in mouse isoform 1) is suitable for producing antibodies that recognize multiple isoforms

  • C-terminal antibodies must account for the SDEL sequence present in AMZ and BMZ forms but absent in AMY forms

• Function-blocking potential:

  • Antibodies targeting the NgR1 binding region (N-terminal half) have shown function-blocking capabilities in experimental settings

How can I address inconsistent results when using OLFM1 antibodies?

Inconsistent results when using OLFM1 antibodies may stem from several factors:

• Isoform variability: Different studies report variable results regarding secretion of different OLFM1 forms, possibly due to antibody reliability issues. The literature notes "difficulties in obtaining reliable antibodies against Olfm1" .

• Protein tag influence: OLFM1 is often tagged with different protein tags to facilitate detection, but "these tags could modify properties of Olfm1" . Consider using both tagged and untagged versions to verify results.

• Glycosylation status: Secreted OLFM1 (heavily glycosylated) may have a different three-dimensional organization and altered binding affinity compared to less glycosylated intracellular OLFM1. This explains why different detection methods (AP-binding assay vs. coimmunoprecipitation) may yield different results .

• Methodological approach: When studying OLFM1-NgR1 interactions, note that the AP assay detects extracellular interactions with heavily glycosylated OLFM1, while coimmunoprecipitation may detect intracellular interactions with less modified OLFM1 .

What controls should be included when using OLFM1 antibodies in functional studies?

When designing functional studies with OLFM1 antibodies, include these essential controls:

• Antibody specificity controls:

  • Preincubation with excess recombinant OLFM1 protein should abolish antibody staining

  • Test antibodies on tissues from knockout models or after siRNA knockdown

  • Include isotype control antibodies to rule out non-specific effects

• Functional blocking controls:

  • When using antibodies to block OLFM1 function, combine exogenous mouse recombinant OLFM1 and anti-OLFM1 together to confirm antibody specificity

  • Quantify the level of inhibition compared to antibody alone

• Cell viability assessment:

  • Perform TUNEL assays to confirm that decreased cell numbers after antibody treatment are not due to cell death

  • Compare apoptotic indices between control and antibody-treated cultures

• Receptor interaction controls:

  • Include soluble NgR1 extracellular domain (~5 nM) as a competitor during binding assays to confirm the specificity of OLFM1-NgR1 interactions

  • Test blocking with antibodies against unrelated receptors as negative controls

How can OLFM1 antibodies be used to distinguish between different cellular responses?

OLFM1 antibodies can be strategically employed to distinguish between various cellular processes:

What are the emerging applications of OLFM1 antibodies in neurological disease research?

Recent research has revealed potential applications of OLFM1 antibodies in studying and treating neurological conditions:

• Axonal regeneration therapy: OLFM1 has been identified as a molecule that "may be used to facilitate neuronal growth after axonal damage" . Antibodies that modulate OLFM1-NgR1 interactions could have therapeutic potential.

• Cancer metastasis inhibition: Function-blocking OLFM1 antibodies significantly reduce neuroblastoma metastasis in experimental models, suggesting potential therapeutic applications .

• Neural development disorders: Given OLFM1's role in neural crest cell production and neuronal differentiation, antibodies targeting this protein may help study developmental abnormalities .

• Pathway-specific modulation: OLFM1 antibodies can be used to specifically inhibit RhoA activation induced by myelin-associated inhibitors, allowing for targeted investigation of this signaling pathway in neurological disorders .

How can advanced imaging techniques be combined with OLFM1 antibodies for in vivo studies?

Integrating advanced imaging techniques with OLFM1 antibodies enables sophisticated in vivo analysis:

• Light sheet confocal microscopy: This technique has been successfully used to image fluorescently labeled NB cells treated with OLFM1 antibodies in avian embryos, allowing for:

  • Quantification of primary tumor escape

  • Analysis of distant metastases

  • Measurement of the distance of metastatic spread

• Embryonic models: OLFM1 antibodies have been used in combination with:

  • DiI labeling for tracing neural projections

  • Whole-mount immunofluorescence for analysis of embryonic structures

  • 3D reconstruction of metastatic patterns

• Quantitative approaches: Advanced image analysis allows researchers to measure:

  • The number and volume of metastatic foci

  • The distance of metastatic spread from primary tumors

  • The morphology of neural structures following antibody treatment

With these methodologies, researchers can comprehensively assess the impact of OLFM1 antibody intervention on both developmental processes and pathological conditions in intact organisms.